Neurimmune is a Swiss, privately-held biotech founded in 2006, specializing in discovering and developing first-in-class antibody therapeutics for protein aggregation diseases. Its core Reverse Translational Medicine™ platform analyzes immune cells from elderly donors to generate fully human antibodies with high selectivity and low immunogenicity risk. The company has built a diversified clinical-stage pipeline targeting ATTR-CM, ALS, and Alzheimer's, advancing programs through strategic partnerships with major pharma while retaining early-stage innovation autonomy.
Reverse Translational Medicine™ - A platform that analyzes immune cells from elderly human subjects to generate fully human therapeutic antibodies with high selectivity for misfolded proteins and low immunogenicity risk.
Funding History
2
GrantUndisclosedUndisclosed
Series AUndisclosedUndisclosed
Opportunities
The company is positioned in large, high-need markets like ATTR-CM and Alzheimer's disease with a novel amyloid depletion mechanism that could offer superior efficacy over standard-of-care.
Successful late-stage data from its partnered programs would provide significant non-dilutive funding via milestones and validate the platform for further internal pipeline expansion and new partnerships.
Risk Factors
High clinical risk associated with late-stage trials in complex diseases like ATTR-CM and ALS.
Heavy reliance on partners for funding and commercialization introduces execution and dependency risks.
The Alzheimer's disease space is intensely competitive, requiring highly differentiated efficacy for success.
Competitive Landscape
In ATTR-CM, Cliramitug competes with TTR stabilizers (tafamidis, diflunisal) and other novel therapies. In Alzheimer's, the market includes approved anti-amyloid antibodies (lecanemab, donanemab) and a crowded pipeline. In ALS, AP-101 targets a specific patient subset (SOD1-ALS), competing with gene therapies and other neuroprotective agents.
